Evidence map›Paper›PMID 25193987›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014

PD-L1 expression in nonclear-cell renal cell carcinoma.

T K Choueiri, A P Fay, K P Gray, M Callea, T H Ho, L Albiges, J Bellmunt, J Song, I Carvo, M Lampron and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03354884 (caBozantinib in cOllectiNg ductS Renal Cell cArcInoma), which is not on this map. Cited by 148 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 6 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03354884 phase2completednot on this mapstarted 2018, after this paper: background citation

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2018 to 2020Enrolled23ConditionsCollecting Duct Carcinoma (Kidney)Armscabozantinib
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 6 syntheses or guidelines pooled it, 298 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

T K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Brigham and Women's Hospital, Boston; Harvard Medical School, Boston. Electronic address: toni_choueiri@dfci.harvard.edu.
A P FayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston.
K P GrayBiostatistics and Computational Biology, Harvard School of Public Health, Boston.
M CalleaDepartment of Pathology, Brigham and Women's Hospital, Boston.
T H HoDepartment of Medical Oncology, Mayo Clinic, Scottsdale.
L AlbigesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston.
J BellmuntDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medical Oncology, Brigham and Women's Hospital, Boston; Harvard Medical School, Boston.
J SongDepartment of Pathology, Brigham and Women's Hospital, Boston.
I CarvoDepartment of Pathology, Brigham and Women's Hospital, Boston.
M LampronDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston.
M L StantonDepartment of Medical Oncology, Mayo Clinic, Scottsdale.
F S HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston.
D F McDermottHarvard Medical School, Boston; Department of Medical Oncology, Beth-Israel Deaconess Medical Center, Boston.
M B AtkinsDepartment of Medical Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, USA.
G J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston.
M S HirschHarvard Medical School, Boston; Department of Pathology, Brigham and Women's Hospital, Boston.
S SignorettiHarvard Medical School, Boston; Department of Pathology, Brigham and Women's Hospital, Boston.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · USMayo Clinic in Arizona · USBeth Israel Deaconess Medical Center · USGeorgetown University Medical Center · US

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA101942-01
6 · The paper itself

Abstract

backgroundProgrammed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown.

methodsFormalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining.

resultsAmong 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P = 0.01) and grade (P = 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P = 0.02 and P = 0.03, respectively).

conclusionIn non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.

Indexed as

AdultAgedAged, 80 and overB7-H1 AntigenCarcinoma, Renal CellFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingSurvival AnalysisYoung AdultB7-H1 AntigenCD274 protein, humanbenign kidney tumorsimmunotherapynonclear-cell renal cell carcinomaPD-1 inhibitorsPD-L1renal cell carcinoma

Identifiers

PMID25193987
PMCPMC4288138
OpenAlexW2140010961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.